ClinicalTrials.gg
CompletedNCT06450132Updated Nov 5, 2026

Changes in Eye Shape With Myopia Management Interventions

A Phase 4 interventional study of Atropine Ophthalmic and MiSight 1-day disposable contact lenses in Myopia, sponsored by Ohio State University. Completed at 1 site in United States. Open to participants aged 21 Years to 30 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Ohio State University · Phase 4, Interventional, and Basic science

How we know

Updated Nov 5, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
21 Years to 30 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 12 studies in Myopia by Ohio State University — 2 open to participants now, 2 under way, 1 of them phase 3. Myopia · Ohio State University.

Enrollment
4th of 10
75 · median 51
Started
2024
with 2 others
Phase 4
Only one
of the 12
Registered
10th of 12
by date

Among the 12 studies in Myopia by Ohio State University, this one is the 4th largest by enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2024, is the only one in phase 4, and was the 10th registered.

Myopia

1,166 studies on the registry are indexed under Myopia; 228 are open to participants now.

Browse Myopia studies →

Open to participants now

2 of the 12 studies in Myopia by Ohio State University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 124 Myopia studies recruiting now, 20 (16%) set no upper age limit and 103 (83%) stop at 75 or younger; 85 take children under 18; 53 take healthy volunteers.

This study: 21 Years to 30 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Myopia by Ohio State University, or all of them as a file.
02

Study summary

The goal of this clinical trial is to study changes in eye shape of nearsighted young adults using low-dose atropine eye drops or soft multifocal contact lenses. The main questions it aims to answer are:

  • do low-dose atropine and soft multifocal contact lenses affect the shape of the peripheral eye?
  • are changes in peripheral eye shape from these interventions influenced by changes in the focusing system of the eye?

Participants will:

  • have multiple different types of photos taken
  • have their prescription for glasses/contacts checked
  • have their eye health checked, including the use of dilating eye drops
  • be randomly assigned to use eye drops every night or wear special contact lenses daily instead of their typical contacts
  • will complete five study visits over the course of 12 months

Researchers will compare young adults using low-dose atropine to those wearing soft multifocal contact lenses and to those using no intervention to see if using these interventions affects retinal shape.

03

Conditions studied

  • Myopia

Browse trials for

04

Who can participate

Ages eligible
21 Years to 30 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • best corrected visual acuity of 20/25 or better in each eye
  • nearsighted
  • current contact lens wearer
  • normal binocular vision (to be determined by an examiner at the first study visit)

Exclusion criteria

Exclusion Criteria:

  • eye diseases (including lazy eye or eye turn)
  • pregnant, nursing, or planning a pregnancy in the next 12 months
  • history of refractive surgery (e.g., LASIK)
  • history of myopia control treatment
  • sensitivity to anesthetics or preservative in eye drops
  • difficulty with pupillary dilation
05

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
75 participants (actual)

Study arms

  • No intervention
    Observation

    Participants randomized to the observation arm will receive no intervention.

  • Experimental
    Low-dose atropine

    Participants randomized to low-dose atropine will instill one drop of 0.05% atropine in each eye at bedtime for 12 months.

    Drug: Atropine Ophthalmic

  • Experimental
    Soft multifocal contact lenses

    Participants randomized to soft multifocal contact lenses will wear MiSight 1-day disposable contact lenses for 5-7 days per week for 12 months.

    Device: MiSight 1-day disposable contact lenses

Interventions

  • DrugAtropine Ophthalmic

    0.05% atropine ophthalmic solution

  • DeviceMiSight 1-day disposable contact lenses

    soft multifocal contact lenses

06

What researchers measure

Primary outcomes

  1. Change in ocular shape

    ocular shape, as measured by the ellipsoid fit of the retina acquired by the photos taken with ocular ultrasound (ABSolu, Quantel Medical)

    Time frame: baseline to 12 months

Secondary outcomes

  1. Axial elongation (or regression)

    change in axial length of the eye, as measured by Lenstar 900 (Haag-Streit)

    Time frame: baseline to 12 months

  2. Change in accommodative response

    change in focusing ability of the eye, as measured with near targets and the Grand Seiko WR-5100K

    Time frame: baseline to 12 months

  3. Change in refractive error

    change in refractive error, as measured with the Grand Seiko WR-5100K

    Time frame: baseline to 12 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Sep 2026, 25 months.

Of 18 phase 4 interventional studies under Myopia, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 29. This study's 25 months is close to that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Jun 2026 → Sep 2026 and completion Jul 2026 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2024
First posted
Jun 10, 2024
StartActual
Aug 1, 2024
Primary completionActual
Sep 4, 2026was Jun 2026
CompletionActual
Sep 4, 2026was Jul 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 5, 2026
Primary completion
Jun 30, 2026→Sep 4, 2026 (actual)
Nov 5, 2026
Study completion
Jul 31, 2026→Sep 4, 2026 (actual)
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Active, not recruiting→Completed
    Primary completion Jun 30, 2026→Sep 4, 2026 (now actual)
    Study completion Jul 31, 2026→Sep 4, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06450132
Responsible party
Donald O Mutti, OD, PhD (EF Wildermuth Foundation Professor in Optometry, Ohio State University) — Principal investigator
First posted
Jun 10, 2024
Start date
Aug 1, 2024
Primary completion
Sep 4, 2026
Completion
Sep 4, 2026
Last update
Nov 5, 2026

Study contacts

Donald O Mutti, OD, PhD
principal investigator · Ohio State University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion